
    
      Following the Confirmation (CF) Phase, participants were randomized to adjunctive LY2216684
      or adjunctive placebo if they had <25% improvement in the Montgomery-Åsberg Depression Rating
      Scale (MADRS) total score over the past 3 weeks and a current MADRS total score ≥14.
      Participants who did not meet criteria received adjunctive placebo to preserve the blind.
    
  